Efficacy of Olanzapine in Addition to Standard Triplet Antiemetic Therapy for Cisplatin-Based Chemotherapy: A Secondary Analysis of the J-FORCE Randomized Clinical Trial

ImportanceIt is unknown whether olanzapine combined with triplet antemetic therapy is effective for all patients undergoing highly emetogenic chemotherapy. A secondary analysis of randomized clinical trials using olanzapine may provide insight into the effectiveness of olanzapine for chemotherapy-induced nausea and vomiting (CINV), including cisplatin. ObjectiveTo examine the add-on effect of olanzapine according to risk factors for CINV. Design, Setting, and ParticipantsThis preplanned secondary analysis evaluated results of the J-FORCE trial, a large double-blind, placebo-controlled phase 3 randomized clinical trial conducted in Japan from February 9, 2017, to July 18, 2018. Participants were enrolled from 26 participating hospitals across Japan and included patients aged 20 to 75 years who had a malignant tumor and were cisplatin-naive. The efficacy analysis population of the J-FORCE trial was analyzed according to allocation adjustment factors (sex [male or female], age [>= 55 years or <55 years], and cisplatin dose [>= 70 mg/m(2) or <70 mg/m(2)]) and patient-related risk factors (history of motion sickness, drinking habit [defined as alcoholic drinks consumption in excess of occasional drinking], and history of morning sickness during pregnancy). Statistical analysis was performed from February 18 to April 18, 2020. InterventionsPatients were randomized 1:1 to receive 5 mg of olanzapine or placebo combined with standard triplet antiemetic therapy. Main Outcomes and MeasuresThe primary end point was complete response (CR, defined as no vomiting and no use of rescue medication) in the delayed phase (24-120 hours after cisplatin-based chemotherapy administration). Secondary end points were CR, complete control, and total control in the acute, delayed, and overall phases for 6 CINV risk factors as well as time to treatment failure. The CR point estimates and 95% CIs of the differences between groups were calculated, and a Mantel-Haenszel test was performed. ResultsOf the 705 patients (mean [SD] age, 63.0 [9.2] years; 471 males [66.8%]) included in the efficacy analysis population; 581 patients (82.4%) were 55 years or older, and 526 (74.6%) were treated with a cisplatin dose of 70 mg/m(2) or more. Risk difference (RD) for a CR in the delayed phase was significantly greater in the olanzapine group than the placebo group in males (RD, 12.6% [95% CI, 5.0%-20.1%]; P=.001); in females (RD, 14.5% [95% CI, 2.2%-26.3%]; P=.02); in those 55 years or older (RD, 11.1% [95% CI, 3.9%-18.2%]; P=.003) or younger than 55 years (RD, 23.6% [95% CI, 7.3%-38.3%]; P=.005); for a cisplatin dose of 70 mg/m(2) or more (RD, 13.5% [95% CI, 5.9%-21.0%]; P<.001); for those without a history of motion sickness (RD, 13.9% [95% CI, 6.9%-20.6%]; P<.001); for those with a drinking habit (RD, 14.9% [95% CI, 6.1%-23.4%]; P=.001) or without a drinking habit (RD, 12.0% [95% CI, 2.5%-21.3%]; P=.01); and for those with a history of morning sickness during pregnancy (RD, 27.2% [9.7%-42.6%]; P=.002). In other subgroups, a delayed CR was higher in the olanzapine group than the placebo group, although not significantly higher. Conclusions and RelevanceResults of this study suggest a benefit of using 5 mg of olanzapine plus triplet antiemetic therapy to counter CINV regardless of the presence or absence of risk factors. Trial RegistrationUniversity Hospital Medical Information Network Clinical Trials Registry Identifier: UMIN000024676